Raloxifene as a multifunctional medicine?: Current trials will show whether it is effective in both osteoporosis and breast cancer

BMJ

Volumn 319, Issue 7206, 1999, Pages 331-332

  Jordan, V Craig ^a   Morrow, M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CHOLESTEROL; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; EDITORIAL; FRACTURE; OSTEOPOROSIS; PRIORITY JOURNAL;

BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; OSTEOPOROSIS; PIPERIDINES; RALOXIFENE;

EID: 0033533207     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.319.7206.331     Document Type: Editorial

References (12)

1. Jordan VC, Phelps E, Lindgren JU. Effect of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10: 31–35.
2. Gottardis MM, Jordan VC. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987; 47: 4020–4024.
3. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Cancer Res 1990; 50: 4177–4189.
4. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Dovey JB, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989; 60: 126–133.
5. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–856.
6. Madigan M, Zeigler R, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well established risk factors. J Natl Cancer Inst 1995; 87: 1681–1685.
7. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–1388.
8. Delmas PD, Bjarnason NH, Mitlack BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–1647.
9. Cumming SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189–2197.
10. Jordan VC, Morrow M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocrine Rev 1999; 20: 253–278.
11. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445–1451.
12. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451–1467.